We are evaluating a new treatment called GLPG5101 for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to understand its safety and effectiveness compared to existing options.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/refractory B-cell non-Hodgkin lymphoma is a type of cancer that occurs when B-cells, a kind of white blood cell, grow uncontrollably. This condition can return after treatment (relapsed) or not respond to treatment (refractory), leading to symptoms such as swollen lymph nodes, fever, night sweats, and unexplained weight loss.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
